Personal information

No personal information available

Activities

Collapse all

Works (50 of 80)

Items per page:
Page 1 of 2

Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network

Blood Advances
2025-01-28 | Journal article
DOI: 10.1182/bloodadvances.2024014171
Contributors: Minoo Battiwalla; Michael Tees; Ian Flinn; Jeremy Pantin; Jesus Berdeja; Tara Gregory; Michael Maris; Vikas Bhushan; Estil Vance; John Mathews et al.
Source: check_circle
Crossref

Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014

Clinical Lymphoma Myeloma and Leukemia
2024-12 | Journal article
DOI: 10.1016/j.clml.2024.07.014
Contributors: Nizar J. Bahlis; Christy Samaras; Donna Reece; Michael Sebag; Jeffrey Matous; Jesús G. Berdeja; Jesse Shustik; Gary J. Schiller; Siddhartha Ganguly; Kevin Song et al.
Source: check_circle
Crossref

Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study

Clinical Lymphoma Myeloma and Leukemia
2024-10 | Journal article
DOI: 10.1016/j.clml.2024.05.014
Contributors: Albert Oriol; Roman Hájek; Ivan Spicka; Irwindeep Sandhu; Yael C. Cohen; Moshe E. Gatt; José Mariz; Michele Cavo; Jesús Berdeja; Kexin Jin et al.
Source: check_circle
Crossref

Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma

American Journal of Hematology
2024-09 | Journal article
DOI: 10.1002/ajh.27382
Contributors: Sosana Delimpasi; Meletios A. Dimopoulos; Jan Straub; Argiris Symeonidis; Luděk Pour; Roman Hájek; Cyrille Touzeau; Viralkumar K. Bhanderi; Jesus G. Berdeja; Petr Pavlíček et al.
Source: check_circle
Crossref

Data from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel

2024-09-16 | Preprint
DOI: 10.1158/2643-3230.c.6816228.v3
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesus G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Data from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel

2024-09-16 | Preprint
DOI: 10.1158/2643-3230.c.6816228
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesus G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Figure S1 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel

2024-09-16 | Preprint
DOI: 10.1158/2643-3230.27025007
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesus G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Figure S1 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel

2024-09-16 | Preprint
DOI: 10.1158/2643-3230.27025007.v1
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesus G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Figure S2 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel

2024-09-16 | Preprint
DOI: 10.1158/2643-3230.27025004
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesus G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Figure S2 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel

2024-09-16 | Preprint
DOI: 10.1158/2643-3230.27025004.v1
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesus G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S1 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel

2024-09-16 | Preprint
DOI: 10.1158/2643-3230.27025001
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesus G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S1 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel

2024-09-16 | Preprint
DOI: 10.1158/2643-3230.27025001.v1
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesus G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S2 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel

2024-09-16 | Preprint
DOI: 10.1158/2643-3230.27024998.v1
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesus G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S2 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel

2024-09-16 | Preprint
DOI: 10.1158/2643-3230.27024998
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesus G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S3 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel

2024-09-16 | Preprint
DOI: 10.1158/2643-3230.27024995
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesus G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S3 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel

2024-09-16 | Preprint
DOI: 10.1158/2643-3230.27024995.v1
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesus G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S4 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel

2024-09-16 | Preprint
DOI: 10.1158/2643-3230.27024992
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesus G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S4 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel

2024-09-16 | Preprint
DOI: 10.1158/2643-3230.27024992.v1
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesus G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S5 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel

2024-09-16 | Preprint
DOI: 10.1158/2643-3230.27024989.v1
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesus G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S5 from Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel

2024-09-16 | Preprint
DOI: 10.1158/2643-3230.27024989
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesus G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia

Hematological Oncology
2024-05 | Journal article
DOI: 10.1002/hon.3274
Contributors: Sudhir Manda; Bertrand M. Anz, III; Christopher Benton; E. Randolph Broun; Habte A. Yimer; John S. Renshaw; George Geils, Jr; Jesus Berdeja; Jose Cruz; Jason M. Melear et al.
Source: check_circle
Crossref

Data from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2024-01-25 | Preprint
DOI: 10.1158/2643-3230.c.6816228.v2
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Figure S1 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2024-01-25 | Preprint
DOI: 10.1158/2643-3230.25062082.v1
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Figure S1 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2024-01-25 | Preprint
DOI: 10.1158/2643-3230.25062082
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Figure S2 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2024-01-25 | Preprint
DOI: 10.1158/2643-3230.25062079.v1
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Figure S2 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2024-01-25 | Preprint
DOI: 10.1158/2643-3230.25062079
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S1 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2024-01-25 | Preprint
DOI: 10.1158/2643-3230.25062076.v1
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S1 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2024-01-25 | Preprint
DOI: 10.1158/2643-3230.25062076
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S2 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2024-01-25 | Preprint
DOI: 10.1158/2643-3230.25062073
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S2 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2024-01-25 | Preprint
DOI: 10.1158/2643-3230.25062073.v1
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S3 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2024-01-25 | Preprint
DOI: 10.1158/2643-3230.25062070
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S3 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2024-01-25 | Preprint
DOI: 10.1158/2643-3230.25062070.v1
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S4 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2024-01-25 | Preprint
DOI: 10.1158/2643-3230.25062067
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S4 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2024-01-25 | Preprint
DOI: 10.1158/2643-3230.25062067.v1
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S5 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2024-01-25 | Preprint
DOI: 10.1158/2643-3230.25062064.v1
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S5 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2024-01-25 | Preprint
DOI: 10.1158/2643-3230.25062064
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study

Clinical Lymphoma Myeloma and Leukemia
2023-12 | Journal article
DOI: 10.1016/j.clml.2023.08.012
Contributors: Myo Htut; Binod Dhakal; Adam D. Cohen; Thomas Martin; Jesus G. Berdeja; Saad Z. Usmani; Mounzer Agha; Carolyn C. Jackson; Deepu Madduri; William Deraedt et al.
Source: check_circle
Crossref

Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma

Blood Advances
2023-10-10 | Journal article
DOI: 10.1182/bloodadvances.2022008866
Contributors: Benjamin A. Derman; Jeffrey Zonder; Donna Reece; Craig Cole; Jesus Berdeja; Andrew T. Stefka; Ajay Major; Andrew Kin; Kent Griffith; Jagoda Jasielec et al.
Source: check_circle
Crossref

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial

Nature Medicine
2023-09 | Journal article
DOI: 10.1038/s41591-023-02496-0
Contributors: Yi Lin; Noopur S. Raje; Jesús G. Berdeja; David S. Siegel; Sundar Jagannath; Deepu Madduri; Michaela Liedtke; Jacalyn Rosenblatt; Marcela V. Maus; Monica Massaro et al.
Source: check_circle
Crossref

Data from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2023-09-01 | Preprint
DOI: 10.1158/2643-3230.c.6816228.v1
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Figure S1 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2023-09-01 | Preprint
DOI: 10.1158/2643-3230.24071511
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Figure S1 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2023-09-01 | Preprint
DOI: 10.1158/2643-3230.24071511.v1
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Figure S2 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2023-09-01 | Preprint
DOI: 10.1158/2643-3230.24071508
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Figure S2 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2023-09-01 | Preprint
DOI: 10.1158/2643-3230.24071508.v1
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S1 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2023-09-01 | Preprint
DOI: 10.1158/2643-3230.24071505.v1
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S1 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2023-09-01 | Preprint
DOI: 10.1158/2643-3230.24071505
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S2 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2023-09-01 | Preprint
DOI: 10.1158/2643-3230.24071502
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S2 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2023-09-01 | Preprint
DOI: 10.1158/2643-3230.24071502.v1
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S3 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2023-09-01 | Preprint
DOI: 10.1158/2643-3230.24071499
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref

Table S3 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

2023-09-01 | Preprint
DOI: 10.1158/2643-3230.24071499.v1
Contributors: Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje et al.
Source: check_circle
Crossref
Items per page:
Page 1 of 2

Peer review (10 reviews for 3 publications/grants)

Review activity for Blood cancer journal. (7)
Review activity for Leukemia (2)
Review activity for Nature medicine. (1)
How many people are using ORCID?